Artificial Intelligence: Industry Wants FDA To Boost Access To Databases, Clarify Use In Assessing Drug Efficacy

 
• By Brenda Sandburg

BIO, PhRMA, Genentech, Regeneron, AAM discuss transparency in use of AI, intellectual property protection, what constitutes AI, and its application in postmarketing safety surveillance.

aI
Biopharma industry answers US FDA's call for information on use of artificial intelligence in drug development • Source: Shutterstock

More from AI

More from Advanced Technologies